Glucose-dependent insulinotropic polypeptide: difference between revisions
Diff·revision 18 → 19·08:02, 21 May 2025
Difference between revision 18 and revision 19 of Glucose-dependent insulinotropic polypeptide. 3 lines changed; the page grew by 187 bytes.
| Revision 18 — 19:26, 16 Apr 2025 ReceptorRhoda (talk) clarify that the incretin effect is defined by the oral–intravenous comparison 6,711 bytes +25 | Revision 19 — 08:02, 21 May 2025 ProglucagonPia (talk) expand §Therapeutic exploitation 6,898 bytes +187 | ||
|---|---|---|---|
| 47 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide oral in type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> | 47 | <ref name="frias2021">Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus semaglutide oral in type 2 diabetes." ''New England Journal of Medicine'' 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.</ref> |
| 48 | 48 | ||
| + | 49 | == Further reading == | |
| + | 50 | * Seino S, Fukushima M, Yabe D. "GIP and GLP-1, the two incretin hormones: Similarities and differences." ''Journal of Diabetes Investigation'' 1(3):8–23 (2010). | |
| + | 51 | ||
| 49 | == See also == | 52 | == See also == |
| 50 | * [[Glucagon-like peptide-1]] | 53 | * [[Glucagon-like peptide-1]] |